title: [Secondary prevention of cytomegalovirus retinitis with ganciclovir].
abstract: The prophylaxis of cytomegalovirus retinitis reactivation is effective in reducing the risk of blindness and in prolonging the remission interval and time of survival if given daily throughout life. In this study, a newly developed therapeutic regimen with 3 infusions a week was compared to the conventional maintenance therapy of 5 infusions a week using the same total weekly dose. For this purpose, ten patients were given 10 mg ganciclovir/kg 3 times a week (group A), and 18 received 6 mg ganciclovir/kg once daily for 5 days a week (group B). Only patients with newly diagnosed retinitis were included in this study. Both groups were comparable regarding their general health and ocular state at the beginning of the study. Induction therapy for stabilization of retinitis had to be given for 17.1 and 16.7 days (P = 0.785). Visual acuity was 0.5 and 0.7, respectively, at the beginning (P = 0.128) and 0.5 each at the end of the study (P = 0.875). Fifty-six percent of both groups presented with central retinal involvement at the beginning, whereas it was 56 and 78%, respectively, at the end (P = 0.250). The retinitis was found to have progressed more than 0.5 papilla diameters (pd) after 63.8 and 64.0 days (P = 0.996) and more than 1 pd after 117.6 and 77.8 days (P = 0.350). New induction therapy had to be performed after 147.9 and 131.5 days, respectively (P = 0.598). The maintenance therapy had to be interrupted due to side effects for 1.4 and 8.3 days, respectively (P = 0.185). According to these results, the prophylaxis of retinitis reactivation with 3 x 10 mg ganciclovir/kg per week is as effective as the established one with 5 x 6 mg/kg per week and can thus be recommended for an improvement in the quality of life for the patients concerned. No problems with this therapy were noted.
authors.affiliation: Universitäts-Augenklinik Bern.
authors.forename: J
authors.initials: J
authors.lastname: Garweg
authors.forename: W
authors.initials: W
authors.lastname: Olszowski
authors.forename: V
authors.initials: V
authors.lastname: Knospe
authors.forename: A
authors.initials: A
authors.lastname: Stoehr
authors.forename: A
authors.initials: A
authors.lastname: Plettenberg
authors.forename: H
authors.initials: H
authors.lastname: Albrecht
authors.forename: H J
authors.initials: HJ
authors.lastname: Stellbrink
authors.forename: L
authors.initials: L
authors.lastname: Weitner
authors.forename: M
authors.initials: M
authors.lastname: Dietrich
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D012008:Recurrence; D012173:Retinitis / Q000188:drug therapy*; D012189:Retrospective Studies; D015215:Zidovudine / Q000008:administration & dosage
chemical_list: D015215:Zidovudine; D015774:Ganciclovir
vernacular_title: Zur Sekundärprophylaxe der Zytomegalieretinitis mit Ganciclovir.